{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:20:16Z","timestamp":1789496416335,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:00:00Z","timestamp":1472601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:00:00Z","timestamp":1472601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advanced, metastatic, castration resistant and chemo-resistant prostate cancer has triggered change in the drug development landscape against prostate cancer. Bovine lactoferrin (bLf) is currently attracting attention in clinics for its anti-cancer properties and proven safety profile. bLf internalises into cancer cells via receptor mediated endocytosis, boosts immunity and complements chemotherapy. We employed bLf as an excellent functional carrier protein for delivering doxorubicin (Dox) into DU145 cells, CD44+\/EpCAM+ double positive enriched DU145 3D prostaspheres and drug resistant ADR1000-DU145 cells, thus circumventing Dox efflux, to overcome chemo-resistance. Successful bLf-Dox conjugation with iron free or iron saturated bLf forms did not affect the integrity and functionality of bLf and Dox. bLf-Dox internalised into DU145 cells within 6\u2009h, enhanced nuclear Dox retention up to 24\u2009h and proved significantly effective (p\u2009&lt;\u20090.001) in reducing LC<jats:sub>50<\/jats:sub> value of Dox from 5.3\u2009\u03bcM to 1.3\u2009\u03bcM (4 fold). Orally fed iron saturated bLf-Dox inhibited tumour development, prolonged survival, reduced Dox induced general toxicity, cardiotoxicity, neurotoxicity in TRAMP mice and upregulated serum levels of anti-cancer molecules TNF-\u03b1, IFN-\u03b3, CCL4 and CCL17. The study identifies promising potential of a novel and safer bLf-Dox conjugate containing a conventional cytotoxic drug along with bLf protein to target drug resistance.<\/jats:p>","DOI":"10.1038\/srep32062","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T16:58:51Z","timestamp":1472662731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice"],"prefix":"10.1038","volume":"6","author":[{"given":"Jayanth Suryanarayanan","family":"Shankaranarayanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagat R.","family":"Kanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrah Jalil Abd","family":"AL-Juhaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupinder K.","family":"Kanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,31]]},"reference":[{"key":"BFsrep32062_CR1","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G","volume":"71","author":"A Yagoda","year":"1993","unstructured":"Yagoda, A. & Petrylak, D. Cytotoxic chemotherapy for advanced hormone\u2010resistant prostate cancer. Cancer 71, 1098\u20131109 (1993).","journal-title":"Cancer"},{"key":"BFsrep32062_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1126\/science.6093249","volume":"226","author":"K Tewey","year":"1984","unstructured":"Tewey, K., Rowe, T., Yang, L., Halligan, B. & Liu, L. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226, 466\u2013468 (1984).","journal-title":"Science"},{"key":"BFsrep32062_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1200\/JCO.1983.1.8.477","volume":"1","author":"FM Torti","year":"1983","unstructured":"Torti, F. M. et al. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. Journal of Clinical Oncology 1, 477\u2013482 (1983).","journal-title":"Journal of Clinical Oncology"},{"key":"BFsrep32062_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1200\/JCO.1994.12.4.683","volume":"12","author":"A Sella","year":"1994","unstructured":"Sella, A. et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. Journal of Clinical Oncology 12, 683\u2013688 (1994).","journal-title":"Journal of Clinical Oncology"},{"key":"BFsrep32062_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/sj.bjc.6603277","volume":"95","author":"L Collins","year":"2006","unstructured":"Collins, L., Zhu, T., Guo, J., Xiao, Z. & Chen, C. Phellinus linteus sensitises apoptosis induced by doxorubicin in prostate cancer. British Journal of Cancer 95, 282\u2013288 (2006).","journal-title":"British Journal of Cancer"},{"key":"BFsrep32062_CR6","doi-asserted-by":"publisher","first-page":"18202","DOI":"10.1073\/pnas.1006965107","volume":"107","author":"A Das","year":"2010","unstructured":"Das, A. et al. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proceedings of the National Academy of Sciences 107, 18202\u201318207 (2010).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"BFsrep32062_CR7","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/S0022-5347(17)35838-X","volume":"150","author":"G Theyer","year":"1993","unstructured":"Theyer, G. et al. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. The Journal of Urology 150, 1544\u20131547 (1993).","journal-title":"The Journal of Urology"},{"key":"BFsrep32062_CR8","doi-asserted-by":"publisher","first-page":"8397","DOI":"10.1158\/0008-5472.can-04-1612","volume":"64","author":"JT Lee","year":"2004","unstructured":"Lee, J. T., Steelman, L. S. & McCubrey, J. A. Phosphatidylinositol 3\u2019-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Research 64, 8397\u20138404, doi:10.1158\/0008-5472.can-04-1612 (2004).","journal-title":"Cancer Research"},{"key":"BFsrep32062_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/jnci\/92.1.34","volume":"92","author":"H Miayake","year":"2000","unstructured":"Miayake, H., Tolcher, A. & Gleave, M. E. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. Journal of the National Cancer Institute 92, 34\u201341 (2000).","journal-title":"Journal of the National Cancer Institute"},{"key":"BFsrep32062_CR10","doi-asserted-by":"publisher","first-page":"38830","DOI":"10.1074\/jbc.M103632200","volume":"276","author":"H Huang","year":"2001","unstructured":"Huang, H. et al. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. The Journal of Biological Chemistry 276, 38830\u201338836, doi:10.1074\/jbc.M103632200 (2001).","journal-title":"The Journal of Biological Chemistry"},{"key":"BFsrep32062_CR11","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.4161\/cbt.4.11.2093","volume":"4","author":"S Thomas","year":"2005","unstructured":"Thomas, S. & Shah, G. Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt\/survivin pathway. Cancer Biology &Ttherapy 4, 1226\u20131233 (2005).","journal-title":"Cancer Biology &Ttherapy"},{"key":"BFsrep32062_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.drudis.2011.04.001","volume":"16","author":"JR Kanwar","year":"2011","unstructured":"Kanwar, J. R., Kamalapuram, S. K. & Kanwar, R. K. Targeting survivin in cancer: the cell-signalling perspective. Drug Discovery Today 16, 485\u2013494 (2011).","journal-title":"Drug Discovery Today"},{"key":"BFsrep32062_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pros.20263","volume":"64","author":"M Zhang","year":"2005","unstructured":"Zhang, M. et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. The Prostate 64, 293\u2013302, doi:10.1002\/pros.20263 (2005).","journal-title":"The Prostate"},{"key":"BFsrep32062_CR14","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1158\/0008-5472.can-06-4608","volume":"67","author":"G Gu","year":"2007","unstructured":"Gu, G., Yuan, J., Wills, M. & Kasper, S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor In vivo. Cancer Research 67, 4807\u20134815, doi:10.1158\/0008-5472.can-06-4608 (2007).","journal-title":"Cancer Research"},{"key":"BFsrep32062_CR15","first-page":"1175","volume":"35","author":"E Hurwitz","year":"1975","unstructured":"Hurwitz, E. et al. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Research 35, 1175\u20131181 (1975).","journal-title":"Cancer Research"},{"key":"BFsrep32062_CR16","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1021\/cb400095v","volume":"8","author":"GR Chamberlain","year":"2013","unstructured":"Chamberlain, G. R., Tulumello, D. V. & Kelley, S. O. Targeted delivery of doxorubicin to mitochondria. ACS Chemical Biology 8, 1389\u20131395, doi:10.1021\/cb400095v (2013).","journal-title":"ACS Chemical Biology"},{"key":"BFsrep32062_CR17","first-page":"450","volume":"20","author":"R Kanwar","year":"2013","unstructured":"Kanwar, R. & Kanwar, J. Immunomodulatory lactoferrin in the regulation of apoptosis modulatory proteins in cancer. Protein and Peptide Letters 20, 450\u2013458 (2013).","journal-title":"Protein and Peptide Letters"},{"key":"BFsrep32062_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0161-5890(03)00152-4","volume":"40","author":"S Farnaud","year":"2003","unstructured":"Farnaud, S. & Evans, R. W. Lactoferrin\u2014a multifunctional protein with antimicrobial properties. Molecular Immunology 40, 395\u2013405 (2003).","journal-title":"Molecular Immunology"},{"key":"BFsrep32062_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2174\/157340611795564286","volume":"7","author":"H Burrow","year":"2011","unstructured":"Burrow, H., Kanwar, R. K. & Kanwar, J. R. Antioxidant enzyme activities of iron-saturated bovine lactoferrin (Fe-bLf) in human gut epithelial cells under oxidative stress. Medicinal Chemistry (Shariqah (United Arab Emirates) 7, 224\u2013230, doi:10.2174\/157340611795564286 (2011).","journal-title":"Medicinal Chemistry (Shariqah (United Arab Emirates)"},{"key":"BFsrep32062_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1139\/o01-239","volume":"80","author":"H Tsuda","year":"2002","unstructured":"Tsuda, H., Sekine, K., Fujita, K.-i. & Iigo, M. Cancer prevention by bovine lactoferrin and underlying mechanisms a review of experimental and clinical studies. Biochemistry and Cell Biology 80, 131\u2013136 (2002).","journal-title":"Biochemistry and Cell Biology"},{"key":"BFsrep32062_CR21","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1002\/jcp.22650","volume":"226","author":"R Jiang","year":"2011","unstructured":"Jiang, R., Lopez, V., Kelleher, S. L. & Lonnerdal, B. Apo- and holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells. Journal of Cellular Physiology 226, 3022\u20133031, doi:10.1002\/jcp.22650 (2011).","journal-title":"Journal of Cellular Physiology"},{"key":"BFsrep32062_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1441-4","volume":"15","author":"JA Gibbons","year":"2015","unstructured":"Gibbons, J. A., Kanwar, J. R. & Kanwar, R. K. Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer. BMC Cancer 15, 1 (2015).","journal-title":"BMC Cancer"},{"key":"BFsrep32062_CR23","doi-asserted-by":"crossref","unstructured":"Kanwar, J. R. et al. Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc. Nanomedicine (London, England), 1\u201321, doi:10.2217\/nnm.14.132 (2014).","DOI":"10.2217\/nnm.14.132"},{"key":"BFsrep32062_CR24","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1248\/bpb.32.523","volume":"32","author":"Y Nojima","year":"2009","unstructured":"Nojima, Y., Iguchi, K., Suzuki, Y. & Sato, A. The pH-dependent formation of PEGylated bovine lactoferrin by branched polyethylene glycol (PEG)-N-hydroxysuccinimide (NHS) active esters. Biological and Pharmaceutical Bulletin 32, 523\u2013526 (2009).","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"BFsrep32062_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jconrel.2008.10.016","volume":"134","author":"K Hu","year":"2009","unstructured":"Hu, K. et al. Lactoferrin-conjugated PEG\u2013PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. Journal of Controlled Release 134, 55\u201361, doi:10.1016\/j.jconrel.2008.10.016 (2009).","journal-title":"Journal of Controlled Release"},{"key":"BFsrep32062_CR26","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1021\/mp4002014","volume":"10","author":"G Kamalinia","year":"2013","unstructured":"Kamalinia, G. et al. Enhanced brain delivery of Deferasirox\u2013Lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: In vitro and in vivo studies. Molecular Pharmaceutics 10, 4418\u20134431, doi:10.1021\/mp4002014 (2013).","journal-title":"Molecular Pharmaceutics"},{"key":"BFsrep32062_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.icb.7100163","volume":"86","author":"JR Kanwar","year":"2008","unstructured":"Kanwar, J. R. et al. \u2018Iron-saturated\u2019lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunology and Cell Biology 86, 277\u2013288 (2008).","journal-title":"Immunology and Cell Biology"},{"key":"BFsrep32062_CR28","doi-asserted-by":"publisher","first-page":"7522","DOI":"10.1016\/j.biomaterials.2014.04.109","volume":"35","author":"RM Samarasinghe","year":"2014","unstructured":"Samarasinghe, R. M., Kanwar, R. K. & Kanwar, J. R. The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosan-nanocarriers on osteoarthritis. Biomaterials 35, 7522\u201334. doi:10.1016\/j.biomaterials.2014.04.109 (2014).","journal-title":"Biomaterials"},{"key":"BFsrep32062_CR29","first-page":"630","volume":"32","author":"SM Yu","year":"2012","unstructured":"Yu, S. M., Peng, Y. P., Yu, S. J. & Lu, H. [FTIR analysis of the impact of covalent coupling on the secondary structure of antibody protein]. Guang Pu Xue Yu Guang Pu Fen Xi\u2009=\u2009Guang Pu 32, 630\u2013634 (2012).","journal-title":"Guang Pu Xue Yu Guang Pu Fen Xi\u2009=\u2009Guang Pu"},{"key":"BFsrep32062_CR30","doi-asserted-by":"publisher","first-page":"9437","DOI":"10.1039\/C2ra21087h","volume":"2","author":"IB Vasconcelos","year":"2012","unstructured":"Vasconcelos, I. B. et al. Cytotoxicity and slow release of the anti-cancer drug doxorubicin from ZIF-8. RSC Advances 2, 9437\u20139442, doi:10.1039\/C2ra21087h (2012).","journal-title":"RSC Advances"},{"key":"BFsrep32062_CR31","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1073\/pnas.92.8.3439","volume":"92","author":"NM Greenberg","year":"1995","unstructured":"Greenberg, N. M. et al. Prostate cancer in a transgenic mouse. Proceedings of the National Academy of Sciences of the United States of America 92, 3439\u20133443 (1995).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep32062_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12929-014-0108-9","volume":"22","author":"N Subramanian","year":"2015","unstructured":"Subramanian, N. et al. EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex. Journal of Biomedical Science 22, 4, doi:10.1186\/s12929-014-0108-9 (2015).","journal-title":"Journal of Biomedical Science"},{"key":"BFsrep32062_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3109\/10409238.2011.614592","volume":"46","author":"JR Kanwar","year":"2011","unstructured":"Kanwar, J. R., Roy, K. & Kanwar, R. K. Chimeric aptamers in cancer cell-targeted drug delivery. Critical Reviews in Biochemistry and Molecular Biology 46, 459\u2013477, doi:10.3109\/10409238.2011.614592 (2011).","journal-title":"Critical Reviews in Biochemistry and Molecular Biology"},{"key":"BFsrep32062_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","volume":"63","author":"V Torchilin","year":"2011","unstructured":"Torchilin, V. Tumor delivery of macromolecular drugs based on the EPR effect. Advanced Drug Delivery Reviews 63, 131\u2013135 (2011).","journal-title":"Advanced Drug Delivery Reviews"},{"key":"BFsrep32062_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0939-6411(00)00076-X","volume":"50","author":"C Leuner","year":"2000","unstructured":"Leuner, C. & Dressman, J. Improving drug solubility for oral delivery using solid dispersions. European journal of Pharmaceutics and Biopharmaceutics 50, 47\u201360 (2000).","journal-title":"European journal of Pharmaceutics and Biopharmaceutics"},{"key":"BFsrep32062_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijpharm.2004.06.009","volume":"282","author":"AA Ambike","year":"2004","unstructured":"Ambike, A. A., Mahadik, K. & Paradkar, A. Stability study of amorphous valdecoxib. International Journal of Pharmaceutics 282, 151\u2013162 (2004).","journal-title":"International Journal of Pharmaceutics"},{"key":"BFsrep32062_CR37","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1021\/mp3004034","volume":"10","author":"A Nasrolahi Shirazi","year":"2013","unstructured":"Nasrolahi Shirazi, A., Tiwari, R., Chhikara, B. S., Mandal, D. & Parang, K. Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs. Mol Pharmaceutics 10, 488\u2013499, doi:10.1021\/mp3004034 (2013).","journal-title":"Mol Pharmaceutics"},{"key":"BFsrep32062_CR38","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/S0006-2952(99)00262-2","volume":"58","author":"\u00d6 Jonsson","year":"1999","unstructured":"Jonsson, \u00d6., Behnam-Motlagh, P., Persson, M., Henriksson, R. & Grankvist, K. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochemical Pharmacology 58, 1801\u20131806 (1999).","journal-title":"Biochemical Pharmacology"},{"key":"BFsrep32062_CR39","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ijc.10246","volume":"98","author":"Y Tada","year":"2002","unstructured":"Tada, Y. et al. Increased expression of multidrug resistance\u2010associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. International Journal of Cancer 98, 630\u2013635 (2002).","journal-title":"International Journal of Cancer"},{"key":"BFsrep32062_CR40","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/leu.2008.79","volume":"22","author":"F Chiarini","year":"2008","unstructured":"Chiarini, F. et al. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 22, 1106\u20131116 (2008).","journal-title":"Leukemia"},{"key":"BFsrep32062_CR41","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1038\/onc.2008.49","volume":"27","author":"LS Steelman","year":"2008","unstructured":"Steelman, L. S. et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 27, 4086\u20134095 (2008).","journal-title":"Oncogene"},{"key":"BFsrep32062_CR42","doi-asserted-by":"publisher","first-page":"38830","DOI":"10.1074\/jbc.M103632200","volume":"276","author":"H Huang","year":"2001","unstructured":"Huang, H. et al. PTEN Induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. Journal of Biological Chemistry. 276, 38830\u201338836, doi:10.1074\/jbc.M103632200 (2001).","journal-title":"Journal of Biological Chemistry."},{"key":"BFsrep32062_CR43","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1093\/annonc\/mdr512","volume":"23","author":"J Van Oosterwijk","year":"2012","unstructured":"Van Oosterwijk, J. et al. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Annals of Oncology 23, 1617\u20131626 (2012).","journal-title":"Annals of Oncology"},{"key":"BFsrep32062_CR44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0006-2952(93)90512-U","volume":"46","author":"A Skladanowski","year":"1993","unstructured":"Skladanowski, A. & Konopa, J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochemical Pharmacology 46, 375\u2013382 (1993).","journal-title":"Biochemical Pharmacology"},{"key":"BFsrep32062_CR45","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/sj.onc.1206366","volume":"22","author":"A Rebbaa","year":"2003","unstructured":"Rebbaa, A., Zheng, X., Chou, P. M. & Mirkin, B. L. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 22, 2805\u20132811 (2003).","journal-title":"Oncogene"},{"key":"BFsrep32062_CR46","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/0006-291X(86)90981-2","volume":"135","author":"JH Doroshow","year":"1986","unstructured":"Doroshow, J. H. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochemical and Biophysical Research Communications 135, 330\u2013335, doi:10.1016\/0006-291X(86)90981-2 (1986).","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"BFsrep32062_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1749-6632.1993.tb17204.x","volume":"698","author":"RL Elliott","year":"1993","unstructured":"Elliott, R. L., Elliott, M. C., Wang, F. E. N. & Head, J. F. Breast carcinoma and the role of iron metabolism. Annals of the New York Academy of Sciences 698, 159\u2013166, doi:10.1111\/j.1749-6632.1993.tb17204.x (1993).","journal-title":"Annals of the New York Academy of Sciences"},{"key":"BFsrep32062_CR48","first-page":"1077","volume":"17","author":"GL David-Beabes","year":"2000","unstructured":"David-Beabes, G. L. et al. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1 and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. International Journal of Oncology 17, 1077\u20131086 (2000).","journal-title":"International Journal of Oncology"},{"key":"BFsrep32062_CR49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/Onc.2013.96","volume":"33","author":"S Zhang","year":"2014","unstructured":"Zhang, S. et al. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene 33, 116\u2013128, doi:10.1038\/Onc.2013.96 (2014).","journal-title":"Oncogene"},{"key":"BFsrep32062_CR50","doi-asserted-by":"publisher","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","volume":"95","author":"LA Doyle","year":"1998","unstructured":"Doyle, L. A. et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proceedings of the National Academy of Sciences 95, 15665\u201315670, doi:10.1073\/pnas.95.26.15665 (1998).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"BFsrep32062_CR51","doi-asserted-by":"publisher","first-page":"25535","DOI":"10.1074\/jbc.M400944200","volume":"279","author":"S Wang","year":"2004","unstructured":"Wang, S. et al. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms: Intermediacy of H2O2- and p53-dependent pathways. Journal of Biological Chemistry 279, 25535\u201325543, doi:10.1074\/jbc.M400944200 (2004).","journal-title":"Journal of Biological Chemistry"},{"key":"BFsrep32062_CR52","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation and cancer. Cell 140, 883\u2013899, doi:10.1016\/j.cell.2010.01.025 (2010).","journal-title":"Cell"},{"key":"BFsrep32062_CR53","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/pros.22597","volume":"73","author":"M Agarwal","year":"2013","unstructured":"Agarwal, M., He, C., Siddiqui, J., Wei, J. T. & Macoska, J. A. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate 73, 573\u2013581, doi:10.1002\/pros.22597 (2013).","journal-title":"Prostate"},{"key":"BFsrep32062_CR54","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/bcr2884","volume":"13","author":"L Gardner","year":"2011","unstructured":"Gardner, L., Malik, R., Shimizu, Y., Mullins, N. & ElShamy, W. M. Geminin overexpression prevents the completion of topoisomerase IIalpha chromosome decatenation, leading to aneuploidy in human mammary epithelial cells. Breast Cancer Research 13, R53, doi:10.1186\/bcr2884 (2011).","journal-title":"Breast Cancer Research"},{"key":"BFsrep32062_CR55","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1021\/mp0500014","volume":"2","author":"TK Jain","year":"2005","unstructured":"Jain, T. K., Morales, M. A., Sahoo, S. K., Leslie-Pelecky, D. L. & Labhasetwar, V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Molecular Pharmaceutics 2, 194\u2013205, doi:10.1021\/mp0500014 (2005).","journal-title":"Molecular Pharmaceutics"},{"key":"BFsrep32062_CR56","doi-asserted-by":"publisher","first-page":"e106568","DOI":"10.1371\/journal.pone.0106568","volume":"9","author":"F Ebrahim","year":"2014","unstructured":"Ebrahim, F. et al. Identification of unprecedented anticancer properties of high molecular weight biomacromolecular complex containing bovine lactoferrin (HMW-bLf). PloS One 9, e106568, doi:10.1371\/journal.pone.0106568 (2014).","journal-title":"PloS One"},{"key":"BFsrep32062_CR57","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1074\/jbc.M707773200","volume":"283","author":"Y Xie","year":"2008","unstructured":"Xie, Y. et al. The 44-kDa Pim-1 kinase phosphorylates BCRP\/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. The Journal of Biological Chemistry 283, 3349\u20133356, doi:10.1074\/jbc.M707773200 (2008).","journal-title":"The Journal of Biological Chemistry"},{"key":"BFsrep32062_CR58","doi-asserted-by":"publisher","first-page":"e12445","DOI":"10.1371\/journal.pone.0012445","volume":"5","author":"D Kong","year":"2010","unstructured":"Kong, D. et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PloS One 5, e12445, doi:10.1371\/journal.pone.0012445 (2010).","journal-title":"PloS One"},{"key":"BFsrep32062_CR59","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1021\/cb400198p","volume":"8","author":"MA Cater","year":"2013","unstructured":"Cater, M. A. et al. Increasing intracellular bioavailable copper selectively targets prostate cancer cells. ACS Chemical Biology 8, 1621\u20131631, doi:10.1021\/cb400198p (2013).","journal-title":"ACS Chemical Biology"}],"updated-by":[{"DOI":"10.1038\/s41598-019-42459-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep32062","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T21:07:14Z","timestamp":1672866434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep32062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,31]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,10,17]]}},"alternative-id":["BFsrep32062"],"URL":"https:\/\/doi.org\/10.1038\/srep32062","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,31]]},"assertion":[{"value":"23 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32062"}}